COVID-19 reinfection: the role of natural immunity, vaccines, and variants

被引:26
作者
Sciscent, Bao Y. [1 ]
Eisele, Caroline D. [1 ]
Ho, Lisa [1 ]
King, Steven D. [1 ]
Jain, Rohit [2 ]
Golamari, Reshma R. [2 ]
机构
[1] Penn State Univ, Coll Med, Hershey, PA USA
[2] Penn State Hlth Milton S Hershey Med Ctr, Dept Hosp Med, Hershey, PA 17033 USA
来源
JOURNAL OF COMMUNITY HOSPITAL INTERNAL MEDICINE PERSPECTIVES | 2021年 / 11卷 / 06期
关键词
COVID-19; reinfection; vaccination; immunity; SARS-CoV-2; SARS-COV-2; VACCINATION; PROTECTION;
D O I
10.1080/20009666.2021.1974665
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The COVID-19 pandemic has altered innumerable lives. Although recent mass vaccinations offer a glimmer of hope, the rising death toll and new variants continue to dominate the current scenario. As we begin to understand more about SARS-CoV-2 infections, the territory of reinfections with COVID-19 remains unexplored. In this review, we will discuss several aspects of reinfection: (a) How is COVID-19 reinfection characterized? (b) Does prior literature differentiate between reinfection and reactivation? (c) What SARS-CoV-2 strains do the vaccines target and can they protect against new strains? Larger and longer timeline studies are needed to understand reinfection risks. With the ongoing distribution of the SARS-CoV-2 vaccines to provide protection, the understanding of the possibility for SARS-CoV-2 reinfection remains critical.
引用
收藏
页码:733 / 739
页数:7
相关论文
共 54 条
  • [1] Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
    Abu-Raddad, Laith J.
    Chemaitelly, Hiam
    Butt, Adeel A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (02) : 187 - 189
  • [2] SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy
    Abu-Raddad, Laith J.
    Chemaitelly, Hiam
    Coyle, Peter
    Malek, Joel A.
    Ahmed, Ayeda A.
    Mohamoud, Yasmin A.
    Younuskunju, Shameem
    Ayoub, Houssein H.
    Al Kanaani, Zaina
    Al Kuwari, Einas
    Butt, Adeel A.
    Jeremijenko, Andrew
    Kaleeckal, Anvar Hassan
    Latif, Ali Nizar
    Shaik, Riyazuddin Mohammad
    Rahim, Hanan F. Abdul
    Nasrallah, Gheyath K.
    Yassine, Hadi M.
    Al Kuwari, Mohamed Ghaith
    Al Romaihi, Hamad Eid
    Al-Thani, Mohamed H.
    Al Khal, Abdullatif
    Bertollini, Roberto
    [J]. ECLINICALMEDICINE, 2021, 35
  • [3] Administration USFD. Janssen COVID-19 Vaccine, 2021, US FOOD DRUG ADM
  • [4] [Anonymous], 2021, VACCINE SPUTNIK
  • [5] Current meta-analysis does not support the possibility of COVID-19 reinfections
    Arafkas, Mohamed
    Khosrawipour, Tanja
    Kocbach, Piotr
    Zielinski, Kacper
    Schubert, Justyna
    Mikolajczyk, Agata
    Celinska, Maria
    Khosrawipour, Veria
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2021, 93 (03) : 1599 - 1604
  • [6] Antibody Response After SARS-CoV-2 Infection and Implications for Immunity A Rapid Living Review
    Arkhipova-Jenkins, Irina
    Helfand, Mark
    Armstrong, Charlotte
    Gean, Emily
    Anderson, Joanna
    Paynter, Robin A.
    Mackey, Katherine
    [J]. ANNALS OF INTERNAL MEDICINE, 2021, 174 (06) : 811 - +
  • [7] What do we know about China's covid-19 vaccines?
    Baraniuk, Chris
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2021, 373
  • [8] Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
    Bernal, Jamie Lopez
    Andrews, Nick
    Gower, Charlotte
    Gallagher, Eileen
    Simmons, Ruth
    Thelwall, Simon
    Stowe, Julia
    Tessier, Elise
    Groves, Natalie
    Dabrera, Gavin
    Myers, Richard
    Campbell, Colin N. J.
    Amirthalingam, Gayatri
    Edmunds, Matt
    Zambon, Maria
    Brown, Kevin E.
    Hopkins, Susan
    Chand, Meera
    Ramsay, Mary
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (07) : 585 - 594
  • [9] Monoclonal Antibody Therapy in a Vaccine Breakthrough SARS-CoV-2 Hospitalized Delta (B.1.617.2) Variant Case
    Connor, Bradley A.
    Couto-Rodriguez, Mara
    Barrows, Joseph E.
    Gardner, Morgan
    Rogova, Marina
    O'Hara, Niamh B.
    Nagy-Szakal, Dorottya
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2021, 110 : 232 - 234
  • [10] Covid-19 vaccines made by China's Sinopharm, 2021, CANOSINO REL EFF DAT